ArticleActa pharmaceutica Sinica. B2022

Design of a highly potent GLP-1R and GCGR dual-agonist for recovering hepatic fibrosis.

Nazi Song et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.